Precision BioSciences, Inc.
DTILHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. Valued at $196.6M, DTIL is a micro-cap name in its sector. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Market Cap
$196.6M
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-4.02
EPS (TTM)
$-2.25
EPS (Fwd)
$-1.89
ROE
-70.9%
ROA
-18.2%
Cash
$101.2M
Total Debt
$28.5M
Free CF
-$21.7M
52W Change
56.8%
Annual Financials
Cash vs Debt
Where DTIL stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, DTIL finished 46.42% above its 150-day moving average ($5.86) and 45.42% above its 200-day moving average ($5.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DTIL overbought or oversold?
At the July 15, 2026 close, DTIL's RSI(14) was 72.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $101.2M in cash comfortably exceeding the $28.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$21.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -70.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.1M (2022) to $34.3M (2025), reflecting a 37% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DTIL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.